

Ninsun Biotech



PIONEERING PREDICTIVE ONCOLOGY

Smarter Immunotherapy (IO)

Vision

We predict the right treatment at the right time

The company

Founded in 2025

Clinical validation stage

Granted patents EU, US, UK, Canada

Experienced management team

Scientific Advisory Board

Pr Nicolas GIRARD, Institut Curie, Paris, Chair

Pr Solange PETERS, CHUV Lausanne

Dr Federico CAPUZZO, NCI, Roma

Dr Christophe GINESTIER, CRC Marseille

Pr Emmanuelle CHARAFE, CRC Marseille



**LUNG
CANCER**

2.5M
New cases/yr

30-50%
treated with IO

1.8M
Deaths/yr

Up to **80%** of patients do not respond to IO !



- ✗ Loss of treatment options
- ✗ Severe toxicity exposure
- ✗ Avoidable healthcare spendings

👉 **Non-response correlated to Cancer Stem Cells (CSC) resistance**



- ✗ There is no reliable biomarker for CSCs
- ✗ CSCs burden in tumor is not assessed

**NinStem Lung Test quantifies CSC burden and empowers clinicians
with the right decision to treat at the right time.**

Designed to fit in PD-L1 testing workflow

A kit prescribed by clinicians, executed by pathology labs


FFPE biopsy/resection

A standard 2h-immunohistochemistry automated assay


100% specificity in CSCs quantification

Granted patents

Cut-off based yes/no decision




✓ Responder



✗ Non-responder

2024



Clinical validation of prognostic value for relapse risk

221 patients, Hospices Civils Lyon, France
Chandouri & al, British Journal of Cancer 2024

2026



Clinical evaluation for predictive performance of response to IO

Retrospective study, 60 patients, Pr Nicolas
GIRARD, Institut Curie - Results by Nov 2026

Heading to a high growth market

Can become a major gate test in immunotherapy

TAM USA + EU **565,000 tests / yr in 2030**

ASP €650 / test, **€367M total market / yr**, 8% CAGR

With a highly competitive positioning

Multiple biomarkers for CSCs with limited specificity
(CD133, Nanog, Sox2, Oct4, EpCam...)

RUO only

2026-2028 Milestones

- 🚩 Clinical validation completed
- ★ CE IVDR submission
- 🏠 Market access engaged
- 💰 Reimbursement discussion engaged

Exciting business development opportunities

Lectin-based drug and radioelements conjugates for
targeted imaging and therapeutics

Filed IP

Seek
€2.8M
by Q4/2026

1st M€ in 2031
GM>90%



Exit targets From 2031

ThermoFisher
SCIENTIFIC



Diagnostics



Agilent Technologies



We predict the right treatment at the right time

*NSC Non Small Cells

Our Core Team



Dr Sylvain
GNAHO
President



Pierre
CHAUMAT
CEO



Dr Boutaina
CHANDOURI-FAIZE
CTO



Dr Vincent
CARRE
CSO



Pr Nicolas
GIRARD
Chief Medical Advisor

Contact info :
Sylvain Gnaho
+33 6 64 78 53 51
sgnao@ninsun-biotech.com